BIIB104 and Working Memory in Schizophrenia
About this title
Read the official source — NCT03745820Researchers compared BIIB104 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Understand this study
What did researchers investigate?
Researchers compared BIIB104 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Bentonville and 59 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 195
- Sponsor
- Biogen
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, United Kingdom, Germany, ...
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT03745820
- Official title
Show the full official title
A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Bentonville, United States · Culver City, United States · Garden Grove, United States
54 more locations
- Lemon Grove, United States
- Long Beach, United States
- Montclair, United States
- Oceanside, United States
- Pico Rivera, United States
- San Diego, United States
- San Rafael, United States
- Torrance, United States
- New Haven, United States
- Lauderhill, United States
- Miami, United States
- Tampa, United States
- Atlanta, United States
- Augusta, United States
- Decatur, United States
- Chicago, United States
- Hoffman Estates, United States
- Springfield, United States
- Gaithersburg, United States
- Grand Rapids, United States
- Flowood, United States
- St Louis, United States
- Berlin, United States
- Buffalo, United States
- Cedarhurst, United States
- Rochester, United States
- Columbus, United States
- North Canton, United States
- Richardson, United States
- San Antonio, United States
- Kirkland, United States
- Bad Homburg, Germany
- Frankfurt am Main, Germany
- Westerstede, Germany
- Leipzig, Germany
- Anan-shi, Japan
- Ichikawa-shi, Japan
- Kashihara-shi, Japan
- Kawasaki-shi, Japan
- Kita-gun, Japan
- Kodaira-shi, Japan
- Kumagaya-shi, Japan
- Takasaki-shi, Japan
- Yokosuka-shi, Japan
- Santander, Spain
- Majadahonda, Spain
- Oviedo, Spain
- Barcelona, Spain
- Madrid, Spain
- Salamanca, Spain
- Seville, Spain
- Oxford, United Kingdom
- Lyne, United Kingdom
- London, United Kingdom
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers compared BIIB104 and placebo to find out how the approaches affected memory, attention and other thinking skills in people with schizophrenia.
Who is behind this study?
The study sponsor is Biogen.
Did this study involve medication?
Yes. The study involved medication, including BIIB104.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
